IBM stock price dips into the weekend as investors brace for Jan. 28 earnings
24 January 2026
1 min read

IBM stock price dips into the weekend as investors brace for Jan. 28 earnings

NEW YORK, Jan 24, 2026, 15:01 ET — Market closed.

  • IBM shares closed Friday in the red and dipped further in after-hours trading.
  • Next week’s earnings will reveal if software and consulting can withstand the volatility in the market.
  • IBM Consulting is rolling out a new AI service based on its proprietary delivery platform.

Shares of International Business Machines Corp slipped 0.76% to close at $292.44 on Friday, then dipped slightly further to $291.99 in after-hours trading as the week wrapped up and investors eyed upcoming events. 1

Attention turns to Wednesday, when IBM is set to release its fourth-quarter results. The company also plans a conference call at 5 p.m. ET, according to its statement. 2

The timing is crucial—earnings season is in full swing, and guidance now moves stocks more than actual results. Investors are focused on how much AI chatter is turning into real revenue, and whether IBM can maintain margins as clients demand faster payoffs.

Broader markets showed little support heading into the weekend. The S&P 500 closed Friday with a modest gain, but the Dow slipped and small caps underperformed. It capped a choppy week marked by tariff warnings and deal scrapping. 3

IBM is pushing a focused message. Its consulting division has launched an “Enterprise Advantage Service,” giving clients access to an internal AI delivery platform designed to scale “agentic AI” — tools that do more than respond to prompts, they take action. The company claims AI assistants have boosted consultant productivity by up to 50%. Still, Mohamad Ali, head of IBM Consulting, admits that “achieving real value at scale remains a major challenge.” 4

Wall Street remains focused on the classic metrics for the quarter: revenue, profit, and guidance. According to a note from Zacks Equity Research cited by Nasdaq, the consensus stands at $4.33 per share on roughly $19.22 billion in revenue, with software sales expected to hit about $8.9 billion. 5

Even if IBM hits the mark, traders will zero in on the breakdown. Software growth usually commands a higher multiple. Consulting demand remains the wildcard, particularly if clients hold back spending or push major projects into Q2.

There’s a downside. If IBM’s outlook suggests clients are pulling back on discretionary spending, or if AI projects remain stuck in pilot phases without scaling, the stock could lose ground fast. The market, eager to punish anything that reads as “good, but not quite good enough,” would react harshly to a soft tone.

IBM’s earnings come during a packed week. According to Kiplinger’s calendar, Wednesday is jammed with reports from Meta, Tesla, IBM, and Starbucks, following a busy start that featured Microsoft. 6

Next on the docket: IBM’s January 28 earnings report, with a close watch on management’s outlook for 2026 demand—particularly in software and consulting linked to AI deployments.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away
Previous Story

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

Novartis stock near a year-high — what investors watch before earnings
Next Story

Novartis stock near a year-high — what investors watch before earnings

Go toTop